Edgar Filing: Gordon David N. - Form 4

• •

Gordon Da Form 4										
March 04, 2								OMB A	PPROVAL	
FOR	UNITED	STATES		RITIES A			COMMISSIO		3235-0287	
if no lo subject Section	to STATE 16.	F CHAN	CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					January 31, 2005 average ırs per		
Form 4 Form 5 obligati may co <i>See</i> Ins 1(b).	Filed put	(a) of the	Public U	Itility Hol	ding Cor		nge Act of 1934, of 1935 or Secti 940		. 0.5	
(Print or Type	e Responses)									
1. Name and Address of Reporting Person <u>*</u> Gordon David N.			Symbol	er Name an Therape			5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (Middle) C/O ACLARIS THERAPEUTICS,			3. Date of Earliest Transaction (Month/Day/Year) 03/01/2019			(Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below)				
INC., 640	LEE ROAD, SUI	ГЕ 200					· · · · · · · · · · · · · · · · · · ·	ef Medical Offic	er	
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting 				
WAYNE,	PA 19087						Person		porting	
(City)	(State)	(Zip)	Tab	ole I - Non-J	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/D	Date, if	3. Transactic Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
				Code V		(D) Price	(Instr. 3 and 4)			
Reminder: Ro	eport on a separate line	e for each cl	ass of sec	urities bene	Perso inforn requir	ns who res nation cont ed to resp lys a curre	or indirectly. Spond to the colle cained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8.1
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	De
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Sec

Edgar Filing: Gordon David N. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired or Dispose (D) (Instr. 3, 4 and 5)	ed of				((In
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Restricted stock units	(1)	03/01/2019		А		82,400		(2)	(2)	Common Stock	82,400	

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Gordon David N. C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE, PA 19087			Chief Medical Officer	
Signatures				
/s/ Mark Ballantyne, Attorney-in-fact	03/04/201	19		

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Date

(2) The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.